Introduction
Tipifarnib (IND 58359; R115777) is a potent and specific farnesyltransferase inhibitor with an IC50 of 0.6 nM. Tipifarnib is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib (Zarnestra; IND 58359; R115777) binds to and inhibits the enzyme farnesyl protein transferase, an enzyme involved in protein processing (farnesylation) for signal transduction. By inhibiting the farnesylation of proteins, it prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.
General Information
| Cas No. | 192185-72-1 |
|---|---|
| Purity | ≥ 98% |
| Molecular Weight | 489.40 |
| Formula | C27H22Cl2N4O |
| Solubility | DMSO：48.94 mg/mL│ethanol；9.79 mg/mL |
| Storage instruction | 2 years -20°C Powder │ 2 weeks 4°C in DMSO │ 6 months -80°C in DMSO |
| Alias | Zarnestra; IND 58359; R115777; IND-58359; IND58359; R-115777; R 115777 |
Product Features:
High Efficiency: Exhibits high selectivity and potency against farnesyltransferase.
Broad Application: Suitable for various cancer research, including hematologic malignancies and solid tumors.
Research Value: Holds significant value in the study of cancer signaling pathways.
Application:
Cancer Research: Used to study the mechanism of farnesyltransferase in cancer.
Drug Development: Developed and tested as a potential anticancer drug.
Cell Biology: Used to investigate the farnesylation process of Ras proteins and their role in cell proliferation.
.png)